Skip to main content


Prostate Cancer

Edited by Suneil Jain and Helen McCarthy (both Queen's University Belfast, UK)

Prostate cancer is the most commonly diagnosed cancer in men. Localized disease is commonly treated with androgen deprivation therapy, surgery or radiotherapy but currently many men develop metastatic castrate resistant prostate cancer.

Novel approaches for early diagnosis and improved therapy are required. This special collection in Cancer Nanotechnology provides a collection of original papers and expert reviews covering a broad range of nanomedical approaches to improving outcomes in prostate cancer.

Nanoparticles have enormous potential to act as radiosensitizers, and targeted therapies are being refined for clinical use with the potential to enhance image guided radiotherapy. Furthermore, many nanoparticles have been designed as drug delivery agents with the promise of delivering increased therapeutic payloads directly to the tumor.

Before submitting your manuscript, please ensure you have carefully read the submission guidelines for Cancer Nanotechnology.

New articles will be added to the collection as they are published.


  1. Content type: Research

    Recent approvals of gene therapies by the FDA and the EMA for treatment of inherited disorders have further opened the door for assessment of nucleic acid pharmaceuticals for clinical usage. Arising from the p...

    Authors: Cian M. McCrudden, John W. McBride, Joanne McCaffrey, Emma M. McErlean, Nicholas J. Dunne, Vicky L. Kett, Jonathan A. Coulter, Tracy Robson and Helen O. McCarthy

    Citation: Cancer Nanotechnology 2018 9:5

    Published on: